Ependymoma

Maximal safe resection remains the cornerstone of management, with radiotherapy or chemotherapy reserved for selected cases. Despite potential morbidity, long-term survival and functional outcomes are favorable for many patients.

Although paraspinal peripheral nerve sheath tumors (including neurofibromas and schwannomas) occur frequently in the NF conditions, there is also a risk of intramedullary spinal cord tumors in people with NF1 and NF2-SWN. Here, we discuss the presentation and diagnosis of the various forms of NF, the intramedullary spinal cord tumors that occur in NF1 and NF2-SWN, and their diagnostic and treatment considerations.

The endoscopic transsphenoidal approach has proven to be a safe and highly effective method for achieving GTR in patients with PPTs. Spindle cell oncocytoma, with a higher level of vascularization than PC and GCT, poses a greater risk of surgical complicationsand may result in non-GTR.

P=N/A, N=370, Recruiting, Institut Claudius Regaud | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Aug 2025 --> Jun 2026

This study emphasizes the heterogeneity of IHG and underscores the necessity for molecular surveillance in recurrent instances. The findings aid in refining diagnostic criteria and understanding the prognostic implications of genetic alterations in IHG.

This single-institution molecularly reclassified series highlights clinically relevant differences between intraventricular and extraventricular pediatric supratentorial ependymomas in presentation, surgical complexity, and treatment burden. Our findings support maximal safe resection as the central therapeutic strategy while emphasizing the value of integrated molecular diagnostics and prolonged surveillance, particularly in light of late recurrence and secondary neoplastic events.

However, further research is needed to explore its functions in other cancers and clarify its molecular mechanisms. Our review synthesizes current knowledge on CXorf67's biological significance, particularly in epigenetics and DNA damage, and its implications in oncogenesis.

P1/2, N=68, Not yet recruiting, Washington University School of Medicine | Trial completion date: Apr 2043 --> Jun 2051

P1, N=50, Active, not recruiting, Children's Oncology Group | Trial completion date: Jul 2043 --> Mar 2033 | Trial primary completion date: Jun 2026 --> Mar 2033

P=N/A, N=80, Active, not recruiting, Children's Oncology Group | Trial completion date: Jul 2031 --> Jul 2032 | Trial primary completion date: May 2031 --> Jul 2032

P1, N=35, Active, not recruiting, Children's Oncology Group | Trial completion date: Feb 2030 --> Dec 2027 | Trial primary completion date: Apr 2027 --> Dec 2027

P1/2, N=63, Terminated, Centre Oscar Lambret | Trial completion date: Jan 2027 --> Dec 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> May 2025; Analysis conducted on spring 2025, according to the provisional schedule: the results were sufficient to conclude about all endpoints, and the sponsor defined a new end of trial on 27 Dec 2025 (modification approved on CTIS on May 26, 2026).